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Abstract
Despite the significant achievements in the management of chronic kidney disease (CKD) 
patients, the mortality rate of these patients still remains high. Nutritional status disor-
ders (NSD) are considered now as one of the prognostic risk factors not only for dialy-
sis but also for predialysis CKD stages. Since the publication of KDIGO 2012 guidelines 
for CKD patient’s management, there has been some significant advancement in our 
understanding of main NSD mechanisms in CKD, including different nosological group 
patients (first, in diabetic and systemic diseases patients). At the same time, there is still 
an urgent need for randomized trials for better-informed decisions and future optimiza-
tion of CKD patients’ care. This chapter provides the current data on all aspects of NSD in 
CKD: etiology, diagnosis, prevention, and treatment approaches, as well as on risk factors 
of NSD at predialysis stages and in chronic hemodialysis patients. Considerable attention 
was devoted to the diagnosis and differential diagnosis of NSD in CKD patients. It was 
determined that the overall strategy for dietary treatment contributed to improving the 
life quality of patients and slowing down of CKD progression. The review is written 
based on the published results of clinical studies performed on the position of evidence-
based medicine.
Keywords: chronic kidney disease, nutrition status disorders, protein energy wasting, 
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1. Introduction
One of the actual problems of nephrology is to improve quality of life and overall survival 
of patients with chronic kidney disease (CKD), the prevalence of which is steadily growing 
throughout the world. Therefore, the retardation of CKD progression and prevention of its 
complications, as well as the delay of renal replacement therapy (RRT) onset, are the primary 
medical and social-economical goal [1–3].
The rate of renal failure progression depends on a range of factors, and among them, nutri-
tional status disorders (NSD) have the important prognostic value [2, 3]. Early detection of NSD 
requires a further in-depth examination of a patient to identify the potential cause (or causes) 
of NSD. NSD develops 2.5 times more often in patients with systemic disease that is caused by 
both the underlying disease activity (increased levels of inflammatory cytokines) and duration 
of corticosteroid therapy in addition to the general CKD risk factors [4]. NSD at predialysis 
CKD stages is found mainly to occur in diabetes mellitus, in patients with severe anemia (hemo-
globin <100 g/l) or with high proteinuria (more than 2.5 g/day), as well as in patients who eat 
low-calorie nutrition (less than 30 kcal/kg/day) [1, 2, 5].
Low-protein diet (LPD) is considered now as more optimal for CKD patients. LPD, reduc-
ing glomerular hypertension, favors decreasing proteinuria as well as hemodynamic dam-
age of renal glomeruli and thus contributing to a slowdown of CKD progression [2, 6, 7]. 
The influence of LPD on CKD progression is more expressed in case of diabetic nephropa-
thy (DN). The annual rate of glomerular filtration rate (GFR) decline in patients who fol-
low LPD and slow down by 1.5–2 times compared with standard diet, and outcome to the 
end-stage of CKD is observed less often almost by three times [5, 7]. Renal protective effects 
of LPD are connected with its hemodynamic and metabolic abilities. The adjustment of pro-
tein and phosphorus contents in the diet in accordance with patient’s residual renal func-
tion contributes to reducing hemodynamic load to the residual nephrons, in addition to the 
decreasing of uremic intoxication. As a result, the glomerular hypertrophy process as well 
as the renin-angiotensin-aldosterone system (RAAS) activation decreases, intraglomerular 
autoregulation normalizes, and intraglomerular and systemic hypertension reduces. LPD 
also partially corrects such unfavorable uremic, metabolic, and endocrine complications, 
such as hypoalbuminemia, dyslipidemia, anemia, hyperphosphatemia with parathyroid 
glands hyperplasia, and thereby it helps to reduce the risk of uremic hyperparathyroidism, 
vascular calcification, and atherosclerosis [2, 8, 9]. LPD in combination with ketoanalogs of 
essential amino acids enhances also antihypertensive and antiproteinuric effects of angio-
tensin receptor blockers (ARB), corrective action of erythropoietins in anemia, effects of 
synthetic vitamin D analogs and calcimimetics on hyperparathyroidism symptoms, and 
hypolipidemic effect of statins [4, 10, 11].
It was found that the mortality rate of dialysis patients is inversely related to the amount of 
protein intake (protein quota), body mass index, and serum albumin [1, 12].
Improvement of the approaches to the early diagnosis, treatment, and prevention of NSD in 
CKD patients is an important strategy to reduce cardiovascular (CV) and overall mortality, 
to increase quality of life, as well as to reduce the cost of hospital and RRT treatment [1, 13].
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The review was written based on the published results of clinical studies performed on the 
position of evidence-based medicine. It is intended not only for nephrologists but also for 
internists, cardiologists, and endocrinologists.
2. Methods
Literature searches were made of 10 major databases among which were PubMed, Medline, 
Embase, Cochrane Library, CINAHL, and e-library. The search was carried out to find all 
articles relevant to CKD and Nutrition Status Disorders. This search encompassed original 
articles, systematic reviews, and meta-analyses. There was no language restriction.
2.1. Agreed criteria for article inclusion in the review
Articles should be full-text. Brief publications and abstracts were not included:
• Research should include at least 20 patients in each group. The minimum mean duration 
of a study was 6 months.
• Analyzed literature over past 15 years.
• The article has the detailed research protocol for assessing its quality.
• Patients examination must meet KDIGO 2012 guidelines.
• Randomized controlled trials.
• Retrospective nonrandomized trials.
3. Nutritional status disorders in chronic kidney disease patients
The International Society of Renal Nutrition and Metabolism (ISRNM) [14] recommended the 
term “Protein-energy wasting (PEW)” to describe the state of decreased body stores of protein 
and energy in CKD patients and proposed a common nomenclature and diagnostic criteria 
for these alterations in the context of CKD.
3.1. Prevalence PEW in CKD
PEW was traditionally considered for a long time as the problem of patients who receive RRT. 
Meanwhile, the results of epidemiological studies conducted for recent years have convinc-
ingly demonstrated that nutritional status disorders appear to be revealed much earlier, before 
dialysis treatment starting, from stages 3B–4 CKD, and impact on prognosis of patients on 
dialysis [1, 2, 12, 13, 15]. The incidence of PEW depends on the stage of CKD (Table 1): among 
CKD patients with a glomerular filtration rate (GFR) of 44–30 ml/min/1.73m2, PEW is detected 
in 4.2% of cases in average, whereas in CKD patients with GFR of 29-15 ml/min/1.73m2 in 
21.3%, and almost all patients with end-stage of CKD have PEW [1, 2, 7, 13, 15, 16].
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At the predialysis stages, PEW is typical for patients with DN because of insulin deficiency or 
insulin resistance, accelerating protein catabolism, as well as due to a high incidence of infectious 
complications, diabetic neuropathy of gastrointestinal tract with malabsorption, [1, 5, 15, 17]; for 
patients with systemic diseases; high proteinuria (more than 2.5 g/day); severe anemia (hemo-
globin <100 g/L); for those who receive prolonged corticosteroid therapy (more than 6 months); 
for patients who eat low-calorie foods (less than 30 kcal/kg/day) [1, 2, 4, 15].
3.2. Etiology and pathogenesis
In contrast to the end products of fat and carbohydrate metabolism (CO2 and H2O) that are excreted through the lungs and skin, the products of protein metabolism can be excreted only 
by kidneys [7, 16].
Qualitative protein food composition is very important because the absence or deficiency of at 
least one of any essential amino acid (EAA) may be a limiting factor for protein biosynthesis 
in the body. Even when the dietary intake provides all amino acids, the body may suffer from 
a protein deficiency if the absorption of any amino acid decreases in the intestine, or when it 
breaks up more than usual under the influence of gut microbiota. In these cases, limited pro-
tein synthesis will occur or the body will compensate for the lack of amino acid required for 
protein biosynthesis by breaking down its own proteins [9, 18]. Changes in protein metabolism 
in uremia are closely related to amino acid metabolism disturbance. Due to a decrease in the 
metabolically active mass of the kidneys, the deficiency of the enzymes synthesized in the 
kidneys, which are necessary for the formation of amino acids, develops [9, 13]. Decrease in 
plasma concentration of EAA can also be largely due to acidosis [15, 17].
The degree of protein and amino acids assimilation from food also depends on the quantitative 
and qualitative composition of carbohydrates and lipids. Experimental and clinical data indicate 
that a diet with insufficient fat and low-calorie diet contribute to the increased oxidation of amino 
acids, intensified degradation, and, partly, even protein synthesis [7, 18]. Protein metabolism, in 
turn, is closely integrated with the exchange of carbohydrates, lipids, and nucleic acids through 
amino acids or α-ketoacids (α-ketoglutarate, oxaloacetate, and pyruvate). Thus, aspartic acid or 
CKD stage Description GFR, ml/min/1.73 m2 Incidence of PEW
1 Kidney damage with normal or increased GFR ≥90 No
2 Kidney damage with mildly decreased GFR 89–60 No
3 59–30
3a Mild-to-moderate decrease in GFR 59–45 No
3b Moderate-to-severe decrease in GFR 44–30 4.2%
4 Severely decreased GFR 29–15 21.3%
5 End-stage of renal failure <15 or RRT onset 74.5%
GFR: glomerular filtration rate, is calculated by CKD-EPI creatinine equation (2009); PEW: protein-energy wasting; and 
RRT: renal replacement therapy.
Table 1. Incidence of PEW depending on CKD stage.
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alanine through the transamination way is reversibly converted to pyruvate oxaloacetate, which 
are subsequently directly included in the carbohydrate metabolism. An inverse relationship was 
found between the leptin concentration and the nutritional status (NS) parameters and a direct 
relationship with the leptin of the C-reactive protein (CRP) [19].
Proteins (and consequently, amino acids as products of their hydrolysis) are directly involved in 
the biosynthesis of a number of hormones and other biologically active compounds that regulate 
metabolic processes in the body. With insufficient intake of protein from food, the protein from its 
own pool disintegrate into free amino acids, which ensure the synthesis of the necessary cytoplas-
mic fractions of protein, enzymes, hormones, and other biologically active compounds [16, 18].
PEW in CKD can also be exacerbated by eating mostly plant proteins of low biological value 
and low-calorie diet. This increases the insulin secretion, which inhibits lipolysis and mobili-
zation of skeletal muscle proteins. These disturbances lead to that the levels of amino acids in 
the blood drop the levels of amino acids in the blood drop, the synthesis of albumin and other 
proteins decreases, leading to hypoalbuminemia. The adaptation mechanism includes hor-
monal changes. These changes help mobilize free fatty acids from adipose tissue and amino 
acids from the muscles. Gluconeogenesis and oxidation of amino acids provide the energy 
that is necessary for the organism-sustaining processes, as a result, protein synthesis is inhib-
ited, metabolism is slowed down, and muscle mass and body fat stores decrease [1, 6, 9].
An important role in the development of PEW is assigned to cytokines and chemokines, 
which begin to accumulate in the blood of patients as the stage of CKD progresses. Cytokines, 
suppressing appetite, cause loss of body weight [13, 18]. Patients with CKD, stages 4–5, are 
prone to negative nitrogen balance and hypercatabolism due to anorexia, inhibition of protein 
and amino acid synthesis, and the deficiency of vitamins and microelements [1, 16].
In acute and chronic infections or immune inflammations, there are effects of tumor necrosis 
factor α (TNF α), interleukin 2 and 6 (IL-2 and IL-6), etc., which also contribute to the develop-
ment of hypoalbuminemia and worsen the prognosis [1, 20].
At the same time,  in  chronic renal failure patients who ignore the use of protein restricted 
diet and consume protein in the amounts greater than recommended for their stage of CKD, 
progressively increased levels of glycation products are observed, which trigger a complex 
cascade of reactions involving the generation of active forms of oxygen. Amino acids, proteins, 
carbohydrates, and lipids (primarily unsaturated fatty acids both free and in the composition 
of phospholipids) are subjected to reactions of free radical oxidation involving reactive oxygen 
species [1, 16]. Acidosis, induced by uncontrolled protein intake, leads to suppression of amino 
acid synthesis, increases their decarboxylation in muscles, and reduces albumin synthesis [17].
3.3. Classification
In clinical practice in the predialysis patient population, PEW is divided into three degrees: 
mild, moderate, and severe [1, 14, 21]. The degree of PEW is established by determining the 
ratio of body weight/recommended body weight × 100%. A decreased ratio down to 80% 
means a mild degree of nutritional disorder, a decrease from 80–70%—moderate, and less 
than 70%—severe nutrition disorder.
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3.4. Clinical presentation
Complaints depending on the underlying pathology that caused signs of PEW: a weight loss 
over the past 6 months, poor appetite, in case of severe PEW—refusal to eat, vomiting, nausea, 
bloating, diarrhea, constipation, abdominal pain, edema, cramps, cough, shortness of breath, 
prolonged fever, anxiety, dry skin, hair loss, deformation of the nails, and weakness.
Medical history allows to identify the kidney disease, which has led to the development of PEW.
3.4.1. Physical examination
Assessment of nutritional status is carried out on a four- or seven-point scale. A seven-point 
scale evaluation is considered more reliable [14, 21, 22].
The following basic criteria are important:
• The dynamics of the patient’s weight since the last examination (usually for 6 months).
• The protein quota intake and calorie content of food calculated according to a 3-day food 
diary; the presence of symptoms of gastrointestinal dysfunction.
• The status of the patient’s fat and muscle mass bases on a visual examination (shoulder 
line, the contouring of clavicles, shoulder blades, and ribs) and palpation (the thickness 
of the fat fold above the biceps and triceps, muscular mass of the triceps, and muscles 
between the thumb and index finger). To objectify the data, the caliper can be used to mea-
sure the fat fold thickness in several places (subscapular region, above the biceps, triceps, 
and iliac crest) and the shoulder circumference in the middle third.
Familiarity with the anamnesis and physical examination reveals the clinical picture of PEW 
[1, 13, 14, 21]:
• Decrease in the body weight by 10% over the last 6 months and shorter period; poor appetite.
• Reduced subcutaneous tissue.
• Possible apathy, fast fatigue, decreased taste, and slowing of peristalsis.
• Subjective assessment (according to seven-point scale) ≤ 5 points.
• Basal metabolic rate and body temperature are lowered due to decreased levels of triiodothy-
ronine (T
3
) below 3.5 pg/ml and loss of the heat-insulating function of the subcutaneous tissue.
3.4.1.1. Mild-to-moderate PEW
Symptoms of nutritional disorders are characterized by a decrease in the body weight 
(by 3–5% per month) and a progressive decrease in appetite with the development of 
anorexia. The thickness of the skin-fat fold (SFFT) above the triceps muscle of the shoulder 
as well as a muscular mass in the shoulder region is reduced. The blood levels of albumin, 
prealbumin, transferrin, and triiodothyronine (T3) decrease. Lymphopenia and impaired 
glucose tolerance may develop.
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3.4.1.2. Severe PEW
It is accompanied by more pronounced changes in clinical and laboratory parameters. Physical 
examination reveals the intercostal depression, atrophy of the temporal muscles, and muscles of 
the extremities. Subcutaneous fat tissue is atrophied or absent. Apathy, rapid fatigue, and a feel-
ing of cold are often symptoms of hypovitaminosis (vitamins B, C, folic acid, D
3
 and B12, and PP); deficiency of trace elements (iron, zinc, copper, and selenium), calcium, arginine and l-carnitine 
are added symptoms; and signs of oxidative stress, aggravating renal anemia, cardiomyopathy, 
myopathy, encephalopathy, and hypertension also accompany. There may be atrophy of intes-
tinal villi and increased growth of microflora in the small intestine.
3.5. Diagnosis
Diagnostic challenges with PEW arise from a variety of causes and also because the body 
weight of patients changes a little due to sodium and water retention and decrease only at the 
last stage of CKD [1, 7, 21, 22].
3.5.1. Anthropometric methods of assessment
Anthropometric methods include determination of body mass index and evaluation of mus-
cle and fat mass of the body [1, 14, 21]. The body mass index (BMI) (Quetelet index, kg/m2) is 
calculated by the formula: BMI = M/L2, where M is the body weight in kilograms and L is the 
height of a person measured in meters and squared.
Measurement of the SFFT by a caliper at 4 points (subscapular region, above the biceps, triceps, 
and iliac crest) allows to calculate the proportion of fat component as a percentage of the total 
body weight, which is 15–16% in healthy men and 25% in women. If the SFFT is reduced by 
more than 10% from the normal value, it indicates a predominant energy insufficiency [1, 14, 22].
The amount of fat in the body (fat mass) can be calculated by the formula: D = d × S × K, where 
D is fat mass (kg); d is the average thickness of the subcutaneous fat layer together with the 
skin (sm) = (d1 + d2 + d3 + d4)/8, where d1 is above the triceps; d2 is above the biceps; d3 is above the shoulder blade; d
4
 is on the abdomen; S is the surface of the body = M0.425 × P0.725 × 71.84 × 10−4, 
where M is the weight (kg), P is height (sm), and K is a constant equal to 1.3.
About the muscle mass, it can be indirectly judged by the formula: SMV (sm) = SC (sm) – 0.314 × 
SFFT (mm), where SMV is the shoulder muscles volume; SC is shoulder circumference at mid-
shoulder level; and SFFT is the skin-fat fold thickness above the triceps at the point of shoulder 
circumference measurement. Deficiency of SMV, exceeding 10%, is typical for protein deficiency.
For dialysis PEW, a combination of muscle deficiency with a decreased volume of adipose tis-
sue is typical. Assessment of anthropometric parameters should be performed in all patients 
with CKD once every 3 months.
Anthropometric criteria of PEW are BMI <18.5 kg/m2; SFFT in men <9.5 mm, in women 
<13 mm; SMV in men <23 cm, in women <21 cm. At the same time, SFFT is a reflection of body 
fat reserves, and SMV is an indicator of the peripheral protein pool.
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3.5.2. Laboratory diagnostics
For the diagnose of impairments in the synthesis of visceral proteins, the determination 
of the content of albumin, transferrin, and lymphocytes number in the blood, as well as 
of the level and spectrum of essential amino acids, is used [1, 14, 21]. The serum albumin 
level only is insufficient for the decision about NS in CKD patients, since its level depends 
on the intravascular volume and the half-life period of albumin is approximately 21 days 
[14]. Therefore, a decrease in the albumin serum level is a relatively a late marker of PEW. 
It should be taken into account that the decrease in serum albumin level may be due to the 
other causes, in addition to PEW. Infections, injuries, and surgical interventions, associated 
with blood and plasma loses; a high level of proteinuria; and disturbances of the protein-
synthetic function of the liver can cause a rapid and significant decrease in serum albumin 
level [14]. On the other hand, prolonged and persistent decrease in serum albumin level 
regardless of its cause always leads to PEW in CKD patients [1, 14]. Hypoalbuminemia is 
closely associated with an increase in concomitant diseases, hospitalizations, and the mortal-
ity rate of CKD patients [1, 3, 20, 23].
The association of hypoalbuminemia with inflammatory process may be established using 
the ratio of the levels of albumin and C-reactive protein in serum [1, 4, 13, 14].
An important diagnostic marker of PEW is also a low serum level of transferrin in the blood 
and is representative of the fraction of beta-globulin; its decrease is observed at an earlier stage 
of protein metabolism disturbance than changes in albumin levels (lifetime of transferrin is 7–8 
days). However, the concentration of transferrin may increase the iron deficiency usually accom-
panying PEW, which should be taken into account in determining the severity of PEW [1, 14, 21].
More accurate markers of the visceral protein pool status are both short-lived transport pro-
teins—prealbumin (lifespan is 2 days) and retino-binding protein (lifespan is 10–12 h). The 
prealbumin level below 0.3 g/l is associated with an increased risk of death and correlates with 
other indicators of PEW [13, 14, 16]. Their content in serum decreases earlier in the case of pro-
tein deficiency in the diet, although it can quickly decrease due to intercurrent diseases [14].
The degree of PEW correlates with the content of lymphocytes in blood [14, 15]. Therefore, 
the absolute number of lymphocytes in the blood can be used to judge the severity of PEW in 
patients with CKD: absolute number of lymphocytes = % of lymphocytes × number of white 
blood cells/100.
The laboratory signs of PEW are serum albumin <35 g/l; serum transferrin <180 mg/dl; and 
absolute number of blood lymphocytes <1800
The study of serum protein counts and the absolute number of lymphocytes should be carried 
out once every 3 months, and if necessary—once every 1.5 months [1, 14].
3.5.3. Instrumental diagnostics
From the instrumental methods for the main body components assessing, the method of 
2-hour bioimpedanceometry is most often used in practical work in connection with the abil-
ity to quantitatively determine not only fatty tissue and muscle mass of the body but also the 
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distribution of fluid in the body [22, 24]. Complex instrumental methods for analyzing NS of 
the body (neutron activation analysis, two-photon X-ray absorptiometry, etc.) are not widely 
available due to high cost.
Bioimpedansometry measures the volume of the total fluid and the proportion of extracellu-
lar and cellular fluids separately, allows to establish a nonfat body mass and a “dry weight,” 
and thus contributes to the selection of an effective mode of HD and ultrafiltration as well as 
the value of the protein quota.
DEXA is a noninvasive method for assessing the condition of the three main body compo-
nents (fatty tissue, muscle mass, bone mass, and bone mineral density). The state of hyperhy-
dration of dialysis patients practically does not affect the accuracy of DEXA. The principle of 
the DEXA method is the scanning of a body in a rectilinear section with the help of two beams 
of photons emitted by an X-ray source. Different tissues (fat, muscle, and bone) absorb X-rays 
in varying degrees. The composition of the body is calculated from the ratio of the natural 
logarithms of the absorbed and unabsorbed beams [14, 22].
Fresenius Medical Care (Germany) company has developed a device that allows to determine 
the individual fluid balance and body composition of the patient—the Body Composition 
Monitor (BCM). The BCM can be used in patients with CKD, regardless of patient’s treatment. 
The measurement is based on the bioimpedance spectroscopy technology, which allows to 
calculate the volume of body water (total, intra-, and extracellular), as well as muscle and fat 
mass of the body (Table 2). Since the total body water (TBW) index is equivalent to the urea 
volume distribution (V), it is not necessary to spend working time for calculating urea kinetic 
modeling and calculating TBW based on anthropometric parameters. Indicator V can be used 
to calculate the dose of dialysis [22].
In addition to the anthropometric (BMI, SFFT, and SMV) and laboratory (albumin, trans-
ferrin, and absolute number of lymphocytes) indicators of NS, the evaluation of protein 
Parameter Gender Age Normal range
BMI, kg/m2 19.5 ± 0.33 (23–18.4)
Body fat mass, % M 20–39
40–59
60–79
12.9 ± 0.65 (19.9–8.0)
18.1 ± 0.41(21.9–11.0)
20.7 ± 0.66 (24.9–13.0)
F 20–39
40–59
60–79
29.1 ± 0.44 (32.9–21.0)
26.4 ± 0.51 (33.9–2.30)
27.8 ± 0.35 (35.9–24.0)
Body muscles mass, % M 18–39
40–59
60–80
35.4 ± 0.75 (39.3–33.3)
37.1 ± 0.85 (39.1–31.1)
34.6 ± 0.31 (38.9–32.9)
F 18–39
40–59
60–80
26.2 ± 0.45 (30.3–24.3)
27.1 ± 0.65 (30.1–24.1)
27.3 ± 0.55 (29.9–23.9)
BMI: body mass index; M: male; F: female; and BIA: bioimpedance analysis.
Table 2. Normal range of nutritional status parameters according to BIA.
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intake and calorie content of food assessed according to a three-day food diary is needed 
[22, 25].
Integrated assessment of nutritional status can be performed also using the malnutrition 
inflammation score (MIS) scale. It allows to analyze anthropometric data (BMI, dry weight 
dynamics, body fat, and muscle mass), gastrointestinal symptoms, dialysis time, labora-
tory data (albumin and blood transferrin), hospitalization rates, and the risk of lethality on 
dialysis [14, 22].
All patients with an identified PEW should be given anthropometric measurements (or bio-
electrical impedance analysis), a clinical and biochemical blood test, and a general urinalysis 
at least one time per 1.5 months, an analysis of protein intake and calorie content on a 3-day 
food diary for at least one time in 3 months [1, 15, 21].
3.6. Differential diagnosis
PEW should be differentiated with a malabsorption syndrome, given a number of common 
manifestations (progressive decrease in BMI and blood albumin). In contrast to malabsorp-
tion, chronic diarrhea with steatorrhea and creatoria is not typical for PEW; while there is 
pronounced increase in serum CRP and TNF-α, calcification of the arteries [1, 14, 20] is found 
[1, 14, 20].
According to the WHO, the diagnostic sign of PEW is a decrease in the mental and physical 
performance of patients, identified as a decrease in the quality of life when determining the 
psychosomatic status according to the standard questionnaires of Kidney Disease Quality of 
life short form (KDQOL-SF) [1].
3.7. Prognosis
Disorders of nutritional status are of great prognostic importance, since they significantly 
impact on the survival and level of rehabilitation of these patients. According to a single-site 
study [23], the mortality rate during the first year on dialysis therapy was 1% in patients with 
a serum albumin level > 38 g/l at the moment of admission to HD treatment, and 30% for 
patients in whom the serum albumin did not exceed 30 g/l.
3.8. Possibilities for PEW correction in CKD: goals and approaches
In CKD patients at the predialysis stage with PEW, the main goal of the treatment is to elimi-
nate the factors contributing to the progression of nutritional disorders and to achieve the 
stabilization of renal failure [1, 14, 21]. The main aim of the diet is to inhibit glomerular hyper-
trophy and intraglomerular hypertension, to reduce the traffic load to tubules, to decrease 
cytokines and uremic toxins production: (TGF-β, ATII, oxygen radicals, TIMP (tissue inhibitor 
matrix metalloproteinases), indoxyl sulfate, guanidine, phosphates, oxalic acid, NO, etc.)
In most patients with CKD and systemic disease (systemic lupus erythematosus, and sys-
temic vasculitis) with persistent disease activity, therapy (correction of the diet and hyper-
tension, suppression of disease activity by glucocorticosteroids (GS) and/or cytostatics) can 
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allow to slow the progression of renal failure and eliminates PEW [1, 4]. However, it should 
be borne in mind that the long-term (more than 6 months) use of CS in CKD patients in pre-
dialysis stages can enhance hypercatabolism, promote the development or aggravation of an 
existing PEW, and therefore careful and regular monitoring of anthropometric indices and 
serum albumin level is required for these patients [1, 13, 14].
LPD with a protein content of 0.6 g/kg body weight/day should be carefully balanced both in 
essential amino acid contents and in calories (at least 34 kcal/kg of ideal body weight/day). 
This requirement must be strictly observed in patients with 4–5 stages of CKD with digestive 
disorders due to uremia and also in patients with stages 3–4 of CKD in systemic diseases with 
persistent disease activity, long-term treatment with GS [1]. When making a 7-day menu, it is 
allowed to substitute products for their protein and carbohydrate equivalents, and to replace 
a portion of the animal protein (0.1 g/kg body weight/day or more) with a high-purity soy-
bean protein (equivalent amount) in the LPD [1, 14, 21, 26].
It is promising to use highly purified soy protein SUPRO-760 (DuPont Protein Technologies 
USA) [1, 13, 14]. Protein “SUPRO” is a protein of high quality, fully digested by the body 
(adjusted amino acid coefficient of protein digestion—1.0). It is prescribed as an additive to 
food at the rate of 0.2–0.3 g soy protein per kg body weight per day [1, 14]. When compil-
ing a diet that includes the soy protein SUPRO-760, the total amount of protein in the diet 
should not exceed 0.7 g/kg of body weight/day, whereas the total caloric value should not be 
less than 30 kcal/kg body weight/day for patients with 3B-5 stages of CKD [1, 14]. In patients 
who are committed to the use of predominantly vegetable protein, as well as in patients with 
anorexia (usually with eGFR <25 ml/min, 1.73 m2), half the daily amount of animal origin pro-
tein in a traditional LPD (0.6 g/kg body weight/day) may be replaced with highly purified soy 
protein [1, 13, 14]. In most of CKD 4–5 stages, patients with anorexia, when using such diet, 
dyspeptic phenomena decreased, blood urea nitrogen level decreased, acidosis corrected, 
and the general condition improved [19].
In the clinical practice of recent years, high-energy nutrient mixtures that are balanced by 
the essential amino acids content such as Fresubin Renal, manufactured by Fresenius Kabi, 
Germany, etc., is introduced in the diet of CKD patients to treat the NSD. These specialized 
mixtures are made on the basis of CKD patients’ requirements in protein, fat, carbohydrate, 
and energy and also enriched with vitamins and minerals.
In the predialysis period of CKD, the use of a low-protein mixture (3 g protein/100 ml) Suplena 
(Abbott Nutrition, USA), with a minimum amount of potassium, sodium, and phosphorus 
balanced with a vitamin-mineral complex, is also promising for prevention and treatment of 
PEW. The energy value of one package of a liquid mixture (237 ml) is 474 kcal [14].
The using of EAA and their α-KA (Ketosteril, Fresenius Kabi ) in the LPD allows to main-
tain the protein balance [1, 6, 10]. EAA and KA are important components of LPD, which 
prevents the development of PEW, and enhance the beneficial effects of LPD [7, 13]. Keto-
analogues, in contrast to the matched their amino acids, do not contain a nitrogen group; by 
capturing endogenous nitrogen they are converted into amino acids in the body, and they 
contribute to the disintegration of urea. The ready-pharmaceutical complex of all EAA and 
KA in the optimal ratio (ketosteril) provides the need of CKD patients in essential amino 
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acids with minimal nitrogen administration, correcting amino acid metabolism, and acceler-
ating urea metabolism, reduces the risk of protein hypercatabolism, and negative nitrogen 
balance when applied diet with protein restriction. This reduces the insulin resistance, ure-
mic dyslipidemia (hypertriglyceridemia), oxidative stress (formation of an active form of 
oxygen, RO—reactive oxygen). The need of EAA and KA addition to LPD is determined by 
the CKD stage (Table 3) [1, 14].
The use of EAA and KA allows to limit protein intake to the required minimum amount to 
enhance the positive effects of LPD and at the same time to prevent the development of PEW 
[6, 11]. With the use of ketoacids, even very low protein intake (up to 0.3 g/kg/day) can be 
achieved without increasing the risk of PEW developing [1]. In patients who were observed 
in predialysis stages of CKD who used LPD and received EAA and KA for at least 12 months, 
there was a significantly lower incidence of NSD and a slower decline in GFR per year than in 
patients who did not limit the protein content in the diet [4].
In patients with 3B-5 stages of CKD, attachment of PEW can contribute to the development 
or aggravation of existing arterial hypertension because of decreased synthesis of nitric oxide 
(NO) due to arginine deficiency. Arginine deficiency in uremia is due to insufficient intake of 
amino acids with food, as well as a decrease in the formation of arginine from citrulline [16, 18]. 
CKD patients with PEW need antihypertensive therapy more than other patients. In CKD, ACE 
inhibitors and ARB have an antihypertensive effect comparable to the effect of calcium channel 
blockers (CCB), but ACE inhibitors and ARB are more likely, than CCB, have a nephroprotec-
tive effect, slowing the progression of renal failure, especially with persistent proteinuria [27]. A 
“strict” LPD in combination with ACE inhibitors (with predominantly hepatic way of elimina-
tion) or ARB in patients with stage 3B-4 CKD and persistent proteinuria more than 1 g/day have 
a joint effect on proteinuria reduction. The antiproteinuric effect is provided by two components: a 
CKD stage GFR (ml/min/1.73 m2) Daily protein intake (g 
protein/kg body weight/
day)
EAA и КA
1 ≥90 0.8 Not required
2 60–89 0.8 Not required
3A
3B
30–59
30–44
0.8
0.6/0.7
Not required
1 tablet/5 kg of body weight/day
4 15–29 1. 0.6
2. 0.3–0.4
1 tablet/5 kg of body weight/day
1 tablet/5 kg of body weight/day
5 >10 to <15
(predialysis)
1. 0.6
2. 0.3–0.4
1 tablet/5 kg of body weight/day
1 tablet/5 kg of body weight/day
GFR: glomerular filtration rate is calculated by CKD-EPI creatinine equation; EAA: essential amino acids; and KA: 
ketoanalogs of amino acids.
Table 3. Essential ketoanalogs and amino acids requirement depending on the diet protein restriction and CKD stage 
(KDIGO guidelines, 2012).
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decrease in the preglomerular vasodilation (due to the restriction of protein intake) and postglo-
merular vasoconstriction (caused by RAAS inhibition), leading to a decrease in intraglomerular 
hyperfiltration, the main determinant of the tubulointerstitial fibrosis progression [1]. In addi-
tion, RAAS blockers in combination with a LPD may affect the maintenance of Klotho products 
as a cardionephroprotective factor [27, 28]
The cardionephroprotective role of ketoacids and LPD was demonstrated in the experiment after 
subtotal nephrectomy. There was a decrease in proteinuria, arterial hypertension, and slowing 
down of left ventricular hypertrophy formation [14]. The retardation of CKD progression is asso-
ciated with a lesser effect of EAA and KA on intra-glomerular hypertension, as well as with its 
ability as an additional source of calcium to correct hyperphosphatemia and slow the formation 
of uremic hyperparathyroidism. LPD in combination with EAA and KA enhances the follow-
ing positive effects: antihypertensive and antiproteinuric effects of RAAS blockers, the corrective 
effect of erythropoietin preparations on anemia and of synthetic analogs of vitamin D, calcimi-
metics on hyperparathyroidism, and also the hypolipidemic effect of statins [1, 13, 14]
At the same time, CKD patients, with combined administration of EAA and active metabo-
lites of vitamin D, due to a possible risk of hypercalcemia should stop taking vitamin D. If 
hypercalcemia persists, then it is necessary to reduce the dose of EAA to normalize the plasma 
concentration of calcium [1]. In recent years, the effect of ketosteril on the risk of vascular cal-
cification has not been confirmed [29].
The addition of soy protein in the diet of patients with 3B-5 stages of CKD may also contrib-
ute to an antihypertensive effect. According to our data, patients with CKD 3B-5 stages who 
added soy protein to food achieved more effective correction of hypertension than patients 
who used milk protein as a food additive [4]. The antihypertensive effect of soy protein is due 
to the isoflavone in it, genistein (an estrogen of plant origin) that has an anti-inflammatory 
effect and a protective effect on the vascular endothelium (8 mg of isoflavone is contained in 
1 g of soy protein). Soy protein contains more than animal protein, arginine (7.6% vs. 3.7%)—
the precursor of NO and glycine (4.2% vs. 1.8%), which inhibit the stress hormone adrenalin 
and contribute to vasodilation [19, 30].
All patients with PEW to reduce the rate of protein catabolism (PCR) should consume at least 
35 kcal/kg of body weight/day [1, 25].
At the same time, in prescribing the caloric content of the diet, in addition to taking into account 
the age, sex, general condition of the patient, and pathogenetic features of the disease, it is nec-
essary to take into consideration the general regimen of the patient. In persons who comply 
with bed rest, energy expenditure will be significantly less than that of patients on a general 
regime. Therefore, the total calorie content of food cannot be the same for all patients [25].
The use of new drug groups, in particular, endothelin-1 receptor agonists, which have an anti-
proteinuric effect, agents that inhibit fibrogenesis and inflammation such as pyrophenidone and 
bardoxolone, as well as an inhibitor of aminoguanidine proteins glycation, are discussed [22].
Based on the available literature data, the correction of NSD, especially early, even at the pre-
dialysis stage not only improves the quality of life of patients but also contributes to  slowing 
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the progression of CKD and CVE, to prevent PEW at the stage of regular HD [12]. Thus, the 
correction of NSD becomes an important and obligatory part in the treatment of patients with 
CKD [1, 14]
3.9. Prophylaxis and dispensary observation
All patients with CKD are advised to consult a dietician, as well as to train in educational 
programs concerning the need to restrict protein, phosphorus, potassium, and salt in the 
diet. Primary prevention of NSD in patients with CKD traditionally is the restriction of pro-
tein in the diet adequately to the reducing degree of GFR. So if at 2–3A stages of CKD with 
GFR >45 ml/min/1.73m2, the recommended daily protein intake is 0.8 g protein/kg/day, then 
with GFR 44-30 ml/min/1.73m2, its intake is limited to 0.7–0.6 g/kg body weight/day and 
0.6–0.3 g/kg body weight/day when GFR 29-15 ml/min/1.73m2 [1, 14]. In CKD patients with 
proteinuria > 3 g/day, the total amount of protein in the daily ration is increased by 1 g 
protein/g of proteinuria [1, 14, 21, 22].
In a diet with a protein restriction of 0.6 g/ kg body weight, at least 60% should be a protein 
of animal origin as the most valuable in the content of EAA. Plant protein has a lower biologi-
cal value, since it does not contain the whole composition of EAA. The exception is the soy 
protein, which is close to the protein of animal origin in the spectrum of EAA [1, 18, 19, 30].
In a “strict” LPD—0.3 g protein/kg/day—the whole protein could be of plant origin but it is 
a mandatory requirement to combine this diet with EAA and their α- keto-analogues [6, 11]. 
However, a strict LPD (but not lower than 0.3 g/kg/day) is permissible only if there are techni-
cal and organizational facilities for regular monitoring of nutritional status, and it should be 
combined with the mandatory intake of EAA and KA.
To ensure that the LPD (0.6–0.3 g protein/kg/day) did not lead to catabolism of the body’s 
own proteins, patients, along with the addition of EAA, should consume at least 35 kcal/kg/day, 
and only in a background of large amounts of protein (0.8–0.7 g/kg/day) the consumption of 
30 kcal/kg/day is sufficient. [25]. High energy value of food should be provided by carbohy-
drates and fats. [14, 25].
Nutritional value of fats is determined by the presence of fatty unsaturated acids (linoleic 
and linolenic) in their composition, which are not synthesized by the body, but come from 
food. The ratio of vegetable oils and animal fats in the diet should be 1:3. Vegetable oil (e.g., 
sunflower, soybean, corn, and cotton) should be present in the daily diet of the patient [14, 22].
The energy value of food is calculated on the basis of the percentage content of carbohydrates, 
fats, and proteins in it, and the coefficient of their biological value. The coefficient of biologi-
cal energy value for carbohydrates is 4 kcal/g, for fats is 9 kcal/g, and for protein is 4 kcal/g. 
Combining the energy value of the protein, fat, and carbohydrates contained in the products, 
the caloric value of the entire diet may be calculated [14, 25].
Patients with a purine metabolism disorders (hyperuricemia and hyperuricosuria) should 
exclude rich broths, by-products—liver, kidneys, heart, tongues, as well as pates, sausages, veal, 
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pork, smoked products, meat and fish canned food, beans (green peas, beans, French beans, and 
lentils), cocoa, chocolate, nuts, strong tea and coffee, grapes, raisins, and grape wines [1, 14].
If oxalic acid is impaired (oxaluria, oxalate kidney stones, and oxalosis), in addition to restric-
tions for patients with elevated uric acid, the consumption of sorrel, spinach, rhubarb, and 
peppers should also be limited [1, 14, 16].
Contraindications to the administration of LPD in CKD are mainly related to patients with 
late 5 stage of CKD (Table 4).
3.10. Pharmacological support for tolerance to a LPD
Long-term compliance with LPD is difficult due to anorexia as well as the tendency of CKD 
patients to protein hypercatabolism. The methods that affect anorexia and hypercatabolism in 
CKD include correction of metabolic acidosis (calcium carbonate, and α-ketoanalogs of EAA), 
deficiency of iron and erythropoietin, elimination of hyperleptinemia (eicosapentaenoic acid), 
and hyperparathyroidism (calcitriol, paricalcitol, and cinacalcet) [1, 13, 14, 21].
Treatment with calcium carbonate in the background of protein-intake restriction increases 
the level of plasma bicarbonate and reduces the protein catabolic rate (PCR) from 1.2 to 1.0 g/day. 
As a result, protein’s catabolism and anorexia that are typical for acidosis are reduced, neu-
tral or positive nitrogen balance is maintained, and parathyroid gland activation is partially 
inhibited [14].
EAA and KA are important components of LPD, which help to prevent the development of 
PEW, correct acidosis, and enhance the beneficial effects of LPD [7, 13]. The need of EAA and 
KA supplementation to LPD is determined by the CKD stage.
The absorption of α-keto acids in the gastrointestinal tract is quick, and their conversion to 
essential amino acids averages from 30% for valine and up to 70% for phenylalanine. The num-
ber of α-keto acids involved in conversion to essential amino acids is inversely  proportional 
Absolute contradiction Relative contradiction
• 5 CKD stage with GFR < 10 ml/min and decompen-
sate metabolic acidosis, uremic polyneuropathy, or 
uncontrolled hypertension
• Cachexia (BMI < 18 kg/m2)
• Rapidly progressive glomerulonephritis
• Severe nephrotic syndrome
• Intolerance to dietary restrictions
• Decompensate diabetes mellitus
• Severe hypercatabolism
• Bacterial infection (acute, exacerbation of chronic 
form)
• Severe anemia
• Noncompliance
• Anorexia
• Psychopathy, mental disorders, encephalopathy
LPD: low-protein diet; GFR: glomerular filtration rate; BMI: body mass index; CKD: chronic kidney disease.
Table 4. Contraindication to LPD in CKD.
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to the daily protein quota in food and directly depends on the caloric content of the diet. Some 
α-keto acids, e.g., ketoisoleucine, in uremia suppress protein degradation in muscles, allow-
ing to maintain a neutral nitrogen balance in conditions of renal failure in the background of 
protein restriction [25].
3.11. Consumption of potassium, sodium, and phosphorus in CKD: water regime
At 3B stage CKD daily intake of potassium, phosphorus in the diet should not exceed 3000 mg 
and 700 mg, respectively, at the 4th stage CKD—potassium intake should be reduced by half. 
LPD allows to reduce the consumption of phosphorus—when consuming 0.6 g/kg protein, 
patients receive 500–800 mg of phosphorus a day, and when the protein quota is limited to 
0.3 g/kg—250 mg of phosphorus. In case of hyperphosphatemia, it should be limited to a fish 
(no more than 1 time per week), as well as cereals (except rice) and other foods rich in phos-
phorus. As an alternative to cereals, artificial sago can be used [1, 14, 26].
In order to correct hyperkalemia, it is recommended to limit the use of dried apricots, figs, 
bananas, apricots, peaches, and nectarines [1, 14].
Restriction of salt intake (no more than 5 g/day) increases the antiproteinuric effectiveness 
of RAAS inhibitors. Exceptions include patients with increased sodium excretion in tubular 
lesions [26].
Most patients with CKD should be recommended a consumption of at least 2 liters of 
fluid/day and up to 3 liters of fluid/day in hot weather, especially when purine metabolism 
is disordered, oxalic acid turnover disturbances, urolithiasis, and a tendency to urinary 
infection [1, 14, 26]
With nephrotic syndrome, as well as in the terminal stage of CKD with a GFR value of less than 
15 ml/min, when the patient cannot form more than 1 l urine/day, the fluid intake is corrected 
by diuresis (300–500 ml to be added to the amount of excreted urine from the previous day) [1].
3.12. Nephroprotective effect of LPD
The nephroprotective effect of LPD is associated with its hemodynamic and metabolic effects. 
The dietary load of protein and phosphorus, according to the possibilities of the residual func-
tion of the kidneys of the patient, in addition to reducing uremic intoxication and lowering 
the level of urea, creatinine, and uric acid in the blood, reduces the hemodynamic load on the 
residual nephrons, which slows the progress of glomerular hypertrophy, as well as activa-
tion of RAAS, normalizes intraglomerular autoregulation, and reduces intra-glomerular and 
systemic arterial hypertension [1, 14]. The LPD partially corrects such unfavorable uremic met-
abolic and endocrine disorders, as hypoalbuminemia, dyslipidemia, insulinoresistance, hyper-
phosphatemia with parathyroid gland hyperplasia, and anemia, and thereby reduces the risk 
of uremic hyperparathyroidism, vascular calcification, and atherosclerosis (Table 5) [7, 20, 26].
The effect of LPD on CKD advancing is more pronounced in cases of DN. In the background 
of LPD, the annual incidence of GFR declines by 1.5–2 times, and the outcome in the terminal 
stage of CKD is observed almost three times less frequently than in the standard diet [5, 7].
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The effect of LPD directly depends on the correct compliance by patients with the prescribed 
restriction of the amount of protein in the diet (0.8–0, 6–0.3 g/kg body weight/day), depending 
on the stage of CKD, the ratio of animal and vegetable proteins in it, and also on high caloric 
intake (30–35 kcal/kg body weight/day) [1, 14, 21].
According to the re-analysis of the MDRD multicentre study (Modification of diet in renal 
disease), in the background of LPD in patients with GFR more than 25 ml/min, the rate of 
CKD progression decreased by approximately 10%, and with GFR less than 25 ml/min, it was 
an average of 30% for every 0.2 g/kg of protein excluded from the diet [1].
The results of the research indicate that “strict” LPD (0.3 g/kg/day of vegetable protein) and the 
use of a complex of EAA and KA (ketosteril 1 table/5 kg of body weight per day) in patients with 
stage 4 CKD provide a more effective reduction of uremia symptoms and provide an extension 
of the predialysis period than conventional LPD (0.6 g protein/kg/day) [6, 11]. Strengthening of 
the nephroprotective role of LPD by combining it with α-ketoanalogs of amino acids is associ-
ated with a lesser effect it has on intra-glomerular hypertension, as well as with their ability as 
an additional source of calcium to inhibit hyperphosphatemia and slow the formation of ure-
mic hyperparathyroidism [1, 11]. LPD in combination with EAA and KA enhances the antihy-
pertensive and antiproteinuric effects of RAAS blockers, the corrective effect of erythropoietin 
preparations on the anemia, the effects of synthetic analogs of vitamin D and calcimimetics on 
manifestations of hyperparathyroidism, and the hypolipidemic effect of statins [10].
Mechanisms of action Clinical effect
Protein restriction to the level, adapted to residual renal 
function
Decrease in level of uremic toxins, azotemia, 
hyperuricemia
Correction of metabolic acidosis Correction of nutrition status:
protein catabolism;
hypoalbuminemia;
amino acids metabolism
Inhibition of glomerular hypertrophy and 
intraglomerular hypertension, decrease in tubular 
transport overload, suppression of cytokines and uremic 
toxins synthesis: TGF-β, AII and RO, TIMP, indoxyl 
sulfate, guanidine, phosphate, oxalic acid, NO
Decrease in proteinuria, correction of hypertension, 
slowing down of glomerulosclerosis and 
tubulointerstitial fibrosis, and GRF stabilization
Partial correction of dyslipidemia:
• of hypercholesteremia;
• of hypertriglyceridemia;
• decrease in insulin resistance
Slowing down of atherosclerosis progression, decrease in 
risk of cardiovascular complications and mortality
Decrease in serum phosphate and PTH levels, increase 
in calcitriol
Suppression of hyperparathyroidism, vascular 
calcification, improvement of anemia, and decrease in 
erythropoietin doses
TGF-β: transforming growth factor β; AII: angiotensin II; RO: reactive oxygen; TIMP: tissue inhibitor matrix 
metalloproteinases; NO: nitrogen oxygen; PTH: parathyroid hormone; and GFR: glomerular filtration rate is calculated 
by CKD EPI creatinine equation.
Table 5. Mechanisms of action and clinical effects of low-protein diet (LPD).
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The replacing of a portion of the animal protein (0.1–0.2 g/kg/day) in the LPD (0.6 g protein/
kg body weight/day) with a highly purified soy protein (an equivalent amount) contributed 
to retardation of CKD progression [4]. Soy protein is less able than animal protein (meat, 
fish, milk, etc.) to increase hyperperfusion and hyperfiltration in remnant nephrons [30]. 
The results of studies on the model of unilateral ureteral obstruction in rats receiving LPD 
demonstrated a decrease in the expression of the nuclear factor of Kappa B transcription 
(NFkB), the most important mediator of activation of many proinflammatory and profi-
brotic cytokines and TGF-β-key as a profibrotic factor in the renal tissue [28, 30]. LPD with 
an addition of soy protein to the diet reduces tubulointerstitial fibrosis also due to sup-
pression of tyrosine protein kinase as a powerful sclerosis stimulant [30]. Currently, the 
possibility of LPD influence to maintain the serum level of klotho protein, as an established 
strong early cardio and nephroprotective factor, is being actively studied [29].
4. Conclusion
Thus, the restriction of daily food protein intake to 0.3–0.6 g/kg/day prevents accumulation of 
toxic products, retards, and delays terminal renal failure. Replacing a portion of the animal pro-
tein in a LPD by an equivalent amount of highly purified soy protein enhances the nephropro-
tective effect of a LPD and favors more pronounced slowdown of CKD progression. The use of 
keto-analogues of essential amino acids with LPD at predialysis stage of CKD allows preserv-
ing CKD patients from nutrition status disorders and contributes to slow down of CKD com-
plications. Control of nutrition status in CKD should be carried out regularly. A comprehensive 
assessment of NS in CKD patients can be quickly performed using bioimpedance analysis.
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